Mobile

A PHASE IIA RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED 5-WAY CROSS-OVER TRIAL TO EXAMINE THE BRONCHODILATOR EFFECTS OF PF-610,355 AND TO TEST FOR SUPERIORITY VERSUS PLACEBO ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-000042-12

A PHASE IIA RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED 5-WAY CROSS-OVER TRIAL TO EXAMINE THE BRONCHODILATOR EFFECTS OF PF-610,355 AND TO TEST FOR SUPERIORITY VERSUS PLACEBO IN REVERSIBLE ASTHMATIC PATIENTS

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To test all doses of PF-610,355 for superiority of trough (24 hour post-dose) FEV1 versus placebo. To characterize the relationship of PF-610,355 dose to peak and trough FEV1

Critère d'inclusion

  • Asthma

Liens